RE "Perhaps we'll simply hear something general saying it was safe in patients treated to date, (it is a safety trial after all), and they've added a new site, etc.
Perhaps they'll mention in general that it's showing signs of efficacy."
In other words, no help for the PPS.
Scratch the HCV/HIV trial off the list of things that might move PP stock.
Monkey paper from Duke (probably will not even list by name PPHM on it) - another nothing.
R&R annual begging for dollars conference - no help there.
Where's that leave shareholders? Hoping for the Gov't contract is about all that's left.